Efficacy and safety of botulinum toxin injection for interstitial cystitis/bladder pain syndrome: a systematic review and meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis/bladder pain syndrome/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn 28(4):274–286. doi: 10.1002/nau.20687
Jhang JF, Kuo HC (2015) Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA injection. Toxins 7(6):2232–2250. doi: 10.3390/toxins7062232
Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A (2015) Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol 193(5):1545–1553. doi: 10.1016/j.juro.2015.01.086
Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ, European Consensus P (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119. doi: 10.1016/j.eururo.2008.09.009
Chancellor MB, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, Aoki KR (2008) Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat Clin Pract Urol 5(6):319–328. doi: 10.1038/ncpuro1124
Chuang YC, Kuo HC, Chancellor MB (2010) Botulinum toxin for the lower urinary tract. BJU Int 105(8):1046–1058
Jankovic J, Brin MF (1991) Therapeutic uses of botulinum toxin. N Engl J Med 324(17):1186–1194. doi: 10.1056/NEJM199104253241707
Gormley EA, Lightner DJ, Faraday M, Vasavada SP, American Urological A, American Urological A, Society of Urodynamics FPM (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580
Chung SD, Kuo YC, Kuo HC (2012) Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Phys 15(3):197–202
Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M (2006) Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol 49(4):704–709. doi: 10.1016/j.eururo.2005.12.002
Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 179(3):1031–1034. doi: 10.1016/j.juro.2007.10.032
Kuo HC, Chancellor MB (2009) Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int 104(5):657–661. doi: 10.1111/j.1464-410X.2009.08495.x
Kuo HC, Jiang YH, Tsai YC, Kuo YC (2015) Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment—a prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. doi: 10.1002/nau.22760
Shie JH, Liu HT, Wang YS, Kuo HC (2013) Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome. BJU Int 111(4):638–646. doi: 10.1111/j.1464-410X.2012.11466.x
Gottsch HP, Miller JL, Yang CC, Berger RE (2011) A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome. Neurourol Urodyn 30(1):93–96. doi: 10.1002/nau.20946
Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E (2014) A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. Int Urogynecol J 25(5):593–599. doi: 10.1007/s00192-013-2267-8
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine 6(7):e1000097. doi: 10.1371/journal.pmed.1000097
Kasyan G, Pushkar D (2012) Randomized controlled trial for efficacy of botulinum toxin type a in treatment of patients suffering bladder pain syndrome/interstitial cystitis with hunners’ lesions: preliminary results. J Urol 187(4 suppl. 1):e335–e336. doi: 10.1016/j.juro.2012.02.912
Chuang YC, Chancellor MB (2006) The application of botulinum toxin in the prostate. The Journal of urology 176(6 Pt 1):2375–2382. doi: 10.1016/j.juro.2006.07.127
da Silva CM, Cruz F (2009) Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it? Curr Opin Urol 19(4):347–352. doi: 10.1097/MOU.0b013e32832ae176
Demidenko E, Sargent J, Onega T (2012) Random effects coefficient of determination for mixed and meta-analysis models. Commun Stat Theory Methods 41(6):953–969. doi: 10.1080/03610926.2010.535631
Chuang YC, Yoshimura N, Huang CC, Chiang PH, Chancellor MB (2004) Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 172(4 Pt 1):1529–1532
Rapp DE, Turk KW, Bales GT, Cook SP (2006) Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J Urol 175(3 Pt 1):1138–1142. doi: 10.1016/S0022-5347(05)00322-8
Chapple C (2014) Chapter 2: pathophysiology of neurogenic detrusor overactivity and the symptom complex of overactive bladder. Neurourol Urodyn 33(Suppl 3):6–13. doi: 10.1002/nau.22635
McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177(3):1071–1077. doi: 10.1016/j.juro.2006.10.055
Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53(6):1236–1244. doi: 10.1016/j.eururo.2008.01.075
Parsons CL, Housley T, Schmidt JD, Lebow D (1994) Treatment of interstitial cystitis with intravesical heparin. Br J Urol 73(5):504–507
Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM, Interstitial Cystitis Clinical Trials G (2003) A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170(3):810–815. doi: 10.1097/01.ju.0000083020.06212.3d
Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford AP, Davis JB, Dasgupta P, Fowler CJ, Anand P (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urology 174(3):977–982; discussion 982–973. doi: 10.1097/01.ju.0000169481.42259.54
Chuang YC, Yoshimura N, Huang CC, Wu M, Chiang PH, Chancellor MB (2009) Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol 56(1):159–166. doi: 10.1016/j.eururo.2008.05.007
Yokoyama O, Miwa Y, Oyama N, Aoki Y, Ito H, Akino H (2007) Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure. J Urol 178(5):2208–2212. doi: 10.1016/j.juro.2007.06.044
Caldwell DM, Ades AE, Higgins JP (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331(7521):897–900. doi: 10.1136/bmj.331.7521.897